Novacyt : 2024 Full Year Results Presentation (EN)

About this update from Novacyt Sas

2024 Full Year Results 30 April 2025 Lyn Rees, Chief Executive Officer CEO of Novacyt Group since 1 May 2024 6 years as CEO of Yourgene Health Drove the acquisition of Elucigene Diagnostics and Coastal Genomics and the fundraising to underpin Prior to joining Yourgene, was Group CEO at British Biocell International (now BBI Group) for over 9 years Completed 7 acquisitions during his tenure at BBI Group Steve Gibson, Chief Financial Officer Joined Novacyt in 2017 Group Finance Director since February 2020, CFO since January 2024 Over 10 years in financial management at a globally recognised blue-chip, technology company Broad commercial and international experience, including IPO CIMA qualified over 15 years International molecular diagnostics company with a growing portfolio of clinical assays, instrumentation and research tools. With deep focus and expertise across reproductive health, precision medicine and infectious disease. Clinical IVD assays & DNA size selection Research qPCR kits Human Health: Reproductive Health - Precision Medicine - Infectious Disease Non-Human Applications: Veterinary & Animal Health - Food, Water & Agriculture - Plant Genomics Locations: Manchester, UK Miami, USA Singapore Canada Commercial presence in over 65 countries Headquartered in Le Vésinet in France Listed on the: London Stock Exchange's AIM market ("NCYT") Paris Stock Exchange Euronext Growth ("ALNOV") Novacyt Group employs around 230 globally

View stock analysis, news, and events for Novacyt Sas